AUVI-Q
Drug
Kaleo, Inc.
Total Payments
$2.0M
Transactions
58,205
Doctors
14,437
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $313,009 | 6,334 | 3,240 |
| 2023 | $301,975 | 10,031 | 4,838 |
| 2022 | $324,844 | 13,255 | 6,651 |
| 2021 | $362,942 | 11,981 | 5,872 |
| 2020 | $345,547 | 6,324 | 3,468 |
| 2019 | $320,752 | 10,280 | 5,257 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1.1M | 57,943 | 54.1% |
| Unspecified | $579,026 | 35 | 29.4% |
| Consulting Fee | $144,674 | 67 | 7.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $102,638 | 77 | 5.2% |
| Space rental or facility fees (teaching hospital only) | $48,820 | 35 | 2.5% |
| Travel and Lodging | $29,563 | 48 | 1.5% |
Payments by Type
General
$1.4M
58,170 transactions
Research
$579,026
35 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Prospective Study of Infant/Toddler Food Challenge Outcomes, Reaction Symptoms and Physiologic Change Post Epinephrine | kaleo, Inc. | $202,278 | 1 |
| A Prospective Study of Infant/Toddler Food Challenge Outcomes, Reaction Symptoms and Physiologic Change Post Epinephrine: Year 2 and the Qualitative Assessment of Parental Experience in Guided Administration of the 0.1mg and 0.15mg Auto-injector | kaleo, Inc. | $201,881 | 1 |
| Trends in Healthcare Utilization and Cost of Infant Anaphylaxis in the United States from 2006-2015; the 44th Multicenter Airway Research Colaboration (MARC-44) Study | kaleo, Inc. | $97,488 | 0 |
| A Prospective Study of InfantToddler Food Challenge Outcomes, Reaction Symptoms and Physiologic Changes Post Epinephrine | kaleo, Inc. | $52,278 | 0 |
| Controlling and preventing astham progression and severity in kids with omalizumab | kaleo, Inc. | $9,827 | 0 |
| Childhood Activities Nutrition and Development Oversight (CANDO) | kaleo, Inc. | $7,007 | 1 |
| Controlling and preventing Asthma progression and Severity in Kids with Omalizumab | kaleo, Inc. | $5,136 | 0 |
| Controlling and preventing Asthma progression and Severity in Kids with Omalizumab | Kaleo, Inc. | $3,131 | 0 |
Top Doctors Receiving Payments for AUVI-Q — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , PA-C | Medical | New York, NY | $878.34 | 38 |
| , MD | Allergy & Immunology | Lakeland, FL | $868.03 | 46 |
| , M.D | Allergy & Immunology | New York, NY | $812.83 | 43 |
| , MD | Allergy & Immunology | Germantown, TN | $801.60 | 44 |
| , PA-C | Medical | Peoria, AZ | $796.60 | 29 |
| , M.D | Allergy & Immunology | Manhasset, NY | $771.53 | 40 |
| , M.D | Internal Medicine | New York, NY | $762.78 | 34 |
| , M.D | Allergy & Immunology | Coral Gables, FL | $734.15 | 34 |
| , M.D | Specialist | New York, NY | $733.37 | 32 |
| , M.D | Allergy | Sarasota, FL | $726.98 | 48 |
| , MD | Internal Medicine | New York, NY | $725.75 | 34 |
| , RPA-C | Physician Assistant | New York, NY | $717.10 | 36 |
| , MD | Internal Medicine | Oklahoma City, OK | $715.07 | 36 |
| , MD | Allergy & Immunology | Louisville, KY | $712.98 | 39 |
| , M.D | Allergy & Immunology | Philadelphia, PA | $712.35 | 42 |
| , MD | Family Medicine | Vienna, VA | $711.03 | 28 |
| , M.D | Allergy | Richmond, VA | $703.26 | 43 |
| , M.D | Allergy & Immunology | Medford, NJ | $701.66 | 49 |
| , M.D | Specialist | New York, NY | $691.54 | 30 |
| , M.D | Internal Medicine | New York, NY | $685.64 | 37 |
| , MD | Allergy & Immunology | Great Neck, NY | $675.13 | 36 |
| , M.D | Allergy & Immunology | Midlothian, VA | $670.86 | 39 |
| , MD | Allergy & Immunology | Walnut Creek, CA | $660.43 | 29 |
| , MD | Allergy & Immunology | Virginia Beach, VA | $660.14 | 33 |
| , M.D | Internal Medicine | Fort Worth, TX | $645.14 | 33 |
Ad
Manufacturing Companies
- kaleo, Inc. $1.7M
- Kaleo, Inc. $263,338
Product Information
- Type Drug
- Total Payments $2.0M
- Total Doctors 14,437
- Transactions 58,205
About AUVI-Q
AUVI-Q is a drug associated with $2.0M in payments to 14,437 healthcare providers, recorded across 58,205 transactions in the CMS Open Payments database. The primary manufacturer is Kaleo, Inc..
Payment data is available from 2019 to 2024. In 2024, $313,009 was paid across 6,334 transactions to 3,240 doctors.
The most common payment nature for AUVI-Q is "Food and Beverage" ($1.1M, 54.1% of total).
AUVI-Q is associated with 8 research studies, including "A Prospective Study of Infant/Toddler Food Challenge Outcomes, Reaction Symptoms and Physiologic Change Post Epinephrine" ($202,278).